• 1
    Bonifazi F, deVivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
  • 2
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of selective inhibitor of Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
  • 3
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;335:2408-2417.
  • 4
    Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk of progression or events in patients in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009;114:Pages. Abstract 1126.
  • 5
    Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108:1478-1484.
  • 6
    Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841-851.
  • 7
    Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123-1129.
  • 8
    Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511-2521.
  • 9
    Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic leukemia patients in early phase. Haematologica. 2010;95:1415-1419.
  • 10
    Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118:3228-3235.
  • 11
    Cross NCP, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172-2175.
  • 12
    Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
  • 13
    Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532-4539.
  • 14
    Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34&plus CML cells. Blood. 2007;109:4016-4019.
  • 15
    Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukaemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukaemia. 2007;21:926-935.
  • 16
    Bhattacharya S, Zheng H, Tzimas C, Carroll M, Baker DP, Fuchs SY. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN via accelerating the degradation of its receptor. Blood. 2011;118:4179-4187.
  • 17
    Essers MA, Offner S, Blanco-Bose WE, et al. IFN-alpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904-908.
  • 18
    Guilhot F, Roy L, Saulnier PJ, Guilhot J. Interferon in chronic myeloid leukaemia: past and future. Best Pract Res Clin Haematol. 2009;22:315-329.
  • 19
    Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634-1642.
  • 20
    Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alpha maintenance after induction therapy with imatinib plus interferon alpha in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28:1429-1435.
  • 21
    Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388.
  • 22
    Lipton JH, Khoroshko N, Golenkov A, et al. Phase II randomized, multicenter, comparative study of peginterferon-alpha-2a (40kD) (Pegasys) versus interferonalpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myeloid leukemia. Leuk Lymphoma. 2007;48:497-505.